335 related articles for article (PubMed ID: 24024144)
21. The Nitric Oxide Prodrug JS-K Induces Ca(2+)-Mediated Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells.
Liu L; Wang D; Wang J; Wang S
J Biochem Mol Toxicol; 2016 Apr; 30(4):192-9. PubMed ID: 26616367
[TBL] [Abstract][Full Text] [Related]
22. JS-K induces reactive oxygen species-dependent anti-cancer effects by targeting mitochondria respiratory chain complexes in gastric cancer.
Zhao X; Cai A; Peng Z; Liang W; Xi H; Li P; Chen G; Yu J; Chen L
J Cell Mol Med; 2019 Apr; 23(4):2489-2504. PubMed ID: 30672108
[TBL] [Abstract][Full Text] [Related]
23. The nitric oxide donor JS-K sensitizes U87 glioma cells to repetitive irradiation.
Heckler M; Osterberg N; Guenzle J; Thiede-Stan NK; Reichardt W; Weidensteiner C; Saavedra JE; Weyerbrock A
Tumour Biol; 2017 Jun; 39(6):1010428317703922. PubMed ID: 28653883
[TBL] [Abstract][Full Text] [Related]
24. The nitric oxide prodrug JS-K and its structural analogues as cancer therapeutic agents.
Maciag AE; Saavedra JE; Chakrapani H
Anticancer Agents Med Chem; 2009 Sep; 9(7):798-803. PubMed ID: 19538173
[TBL] [Abstract][Full Text] [Related]
25. Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs.
Nandurdikar RS; Maciag AE; Holland RJ; Cao Z; Shami PJ; Anderson LM; Keefer LK; Saavedra JE
Bioorg Med Chem; 2012 May; 20(9):3094-9. PubMed ID: 22480849
[TBL] [Abstract][Full Text] [Related]
26. Role of human glutathione transferases in biotransformation of the nitric oxide prodrug JS-K.
Sjödin B; Mannervik B
Sci Rep; 2021 Oct; 11(1):20765. PubMed ID: 34675290
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of action for the cytotoxic effects of the nitric oxide prodrug JS-K in murine erythroleukemia cells.
Kaczmarek MZ; Holland RJ; Lavanier SA; Troxler JA; Fesenkova VI; Hanson CA; Cmarik JL; Saavedra JE; Keefer LK; Ruscetti SK
Leuk Res; 2014 Mar; 38(3):377-82. PubMed ID: 24461365
[TBL] [Abstract][Full Text] [Related]
28. Effects of JS-K, a novel anti-cancer nitric oxide prodrug, on gene expression in human hepatoma Hep3B cells.
Dong R; Wang X; Wang H; Liu Z; Liu J; Saavedra JE
Biomed Pharmacother; 2017 Apr; 88():367-373. PubMed ID: 28122301
[TBL] [Abstract][Full Text] [Related]
29. Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug.
Findlay VJ; Townsend DM; Saavedra JE; Buzard GS; Citro ML; Keefer LK; Ji X; Tew KD
Mol Pharmacol; 2004 May; 65(5):1070-9. PubMed ID: 15102935
[TBL] [Abstract][Full Text] [Related]
30. JS-K, a GST-activated nitric oxide donor prodrug, enhances chemo-sensitivity in renal carcinoma cells and prevents cardiac myocytes toxicity induced by Doxorubicin.
Qiu M; Ke L; Zhang S; Zeng X; Fang Z; Liu J
Cancer Chemother Pharmacol; 2017 Aug; 80(2):275-286. PubMed ID: 28608259
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and evaluation of piperazine and homopiperazine analogues of JS-K, an anti-cancer lead compound.
Nandurdikar RS; Maciag AE; Citro ML; Shami PJ; Keefer LK; Saavedra JE; Chakrapani H
Bioorg Med Chem Lett; 2009 May; 19(10):2760-2. PubMed ID: 19364650
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and in vitro anti-leukemic activity of structural analogues of JS-K, an anti-cancer lead compound.
Chakrapani H; Goodblatt MM; Udupi V; Malaviya S; Shami PJ; Keefer LK; Saavedra JE
Bioorg Med Chem Lett; 2008 Feb; 18(3):950-3. PubMed ID: 18178089
[TBL] [Abstract][Full Text] [Related]
33. JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C).
Shami PJ; Maciag AE; Eddington JK; Udupi V; Kosak KM; Saavedra JE; Keefer LK
Leuk Res; 2009 Nov; 33(11):1525-9. PubMed ID: 19193435
[TBL] [Abstract][Full Text] [Related]
34. JS-K, a nitric oxide prodrug, induces DNA damage and apoptosis in HBV-positive hepatocellular carcinoma HepG2.2.15 cell.
Liu Z; Li G; Gou Y; Xiao D; Luo G; Saavedra JE; Liu J; Wang H
Biomed Pharmacother; 2017 Aug; 92():989-997. PubMed ID: 28605880
[TBL] [Abstract][Full Text] [Related]
35. Permeability changes in response to NONOate and NONOate prodrug derived nitric oxide in a blood-brain barrier model formed by primary porcine endothelial cells.
Winter S; Konter J; Scheler S; Lehmann J; Fahr A
Nitric Oxide; 2008 May; 18(3):229-39. PubMed ID: 18284923
[TBL] [Abstract][Full Text] [Related]
36. Effect of a Pluronic(®) P123 formulation on the nitric oxide-generating drug JS-K.
Kaur I; Kosak KM; Terrazas M; Herron JN; Kern SE; Boucher KM; Shami PJ
Pharm Res; 2015 Apr; 32(4):1395-406. PubMed ID: 25330743
[TBL] [Abstract][Full Text] [Related]
37. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies.
Velázquez C; Praveen Rao PN; Knaus EE
J Med Chem; 2005 Jun; 48(12):4061-7. PubMed ID: 15943479
[TBL] [Abstract][Full Text] [Related]
38. Synergistic apoptosis of CML cells by buthionine sulfoximine and hydroxychavicol correlates with activation of AIF and GSH-ROS-JNK-ERK-iNOS pathway.
Chowdhury AA; Chaudhuri J; Biswas N; Manna A; Chatterjee S; Mahato SK; Chaudhuri U; Jaisankar P; Bandyopadhyay S
PLoS One; 2013; 8(9):e73672. PubMed ID: 24040019
[TBL] [Abstract][Full Text] [Related]
39. Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: Structural analogues of PABA/NO, an anti-cancer lead compound.
Chakrapani H; Wilde TC; Citro ML; Goodblatt MM; Keefer LK; Saavedra JE
Bioorg Med Chem; 2008 Mar; 16(5):2657-64. PubMed ID: 18060792
[TBL] [Abstract][Full Text] [Related]
40. JS-K, a nitric oxide-releasing prodrug, modulates ß-catenin/TCF signaling in leukemic Jurkat cells: evidence of an S-nitrosylated mechanism.
Nath N; Chattopadhyay M; Pospishil L; Cieciura LZ; Goswami S; Kodela R; Saavedra JE; Keefer LK; Kashfi K
Biochem Pharmacol; 2010 Dec; 80(11):1641-9. PubMed ID: 20797387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]